Pityriasis lichenoides chronica treated with combination of Narrowband Ultraviolet B (NBUVB) phototherapy and erytrhomycin
DOI:
https://doi.org/10.66344/jpad.v36i1.3250Keywords:
Pityriasis lichenoides chronica, phototherapy, NBUVB, erythromycinAbstract
Pityriasis lichenoides chronica (PLC) is a rare skin disorder that often resists treatment. Its etiology remains unclear but may involve triggers such as infections or medications that induce an inflammatory skin response. Recent studies have investigated treatment options for PLC, including narrowband ultraviolet B (NBUVB) phototherapy and systemic antibiotics like erythromycin. NBUVB delivers targeted anti-inflammatory effects to promote lesion clearance and minimize systemic side effects for localized conditions. Erythromycin, a macrolide antibiotic, has shown efficacy in PLC, particularly among pediatric patients, because of its anti-inflammatory mechanisms alongside antimicrobial activity. We describe a 16-year-old girl with PLC featuring erythematous papules across nearly her entire body for 2 years. Diagnosis relied on clinical history, physical examination, and histopathology. Topical corticosteroids proved ineffective. The patient then underwent combined NBUVB phototherapy and erythromycin therapy, with no side effects reported and notable lesion improvement. This dual approach offers a comprehensive strategy for PLC by targeting inflammation via NBUVB and addressing potential infectious elements with erythromycin.References
Elbendary A, Abdel‐Halim MR, Youssef R, Abdel Halim D, Elmasry MF, Gad A, El Sharkawy DA. Hypopigmented lesions in pityriasis lichenoides chronica patients: Are they only post‐inflammatory hypopigmentation? Australas J Dermatol. 2022 Feb;63(1):68-73.
Feola H, Mancinelli MC, Perez‐Klala MV, Verea MA. Pityriasis lichenoides chronica: Rapid response after a single cycle of azithromycin therapy. Dermatol Ther. 2020 May 1;33(3): e13303.
Al Muqrin AM, Alruwaili ZM. Pityriasis lichenoides chronica induced by COVID-19 messenger RNA vaccination. JAAD Case Rep. 2022 Jul 19;27:52.
Duzett L, Mercado G, Tasouli-Drakou V, Kane A, Tam A. Pityriasis following COVID-19 vaccinations: a systematic review. Dermatol Rep. 2023 Aug 9;16(1):9742.
Elbendary A, Youssef R, Abdel-Halim MR, Abdel Halim D, El Sharkawy DA, Alfishawy M, Gad MA, Gad A, Elmasry MF. Role of streptococcal infection in the etiopathogenesis of pityriasis lichenoides chronica and the therapeutic efficacy of azithromycin: a randomized controlled trial. Arch Dermatol Res. 2023 Apr;315(3):521-30.
Jung F, Sibbald C, Bohdanowicz M, Ingram JR, Piguet V. Systematic review of the efficacies and adverse effects of treatments for pityriasis lichenoides. Br J Dermatol. 2020 Dec 1;183(6):1026-32.
Agaoglu E, Erdogan HK, Acer E, Saracoglu ZN, Bilgin M. Narrowband ultraviolet B phototherapy for pityriasis lichenoides: A real‐life experience. Photodermatol Photoimmunol Photomed. 2023 Sep;39(5):520-6.
Gupta S, Namdeo C, Bhatia K. Efficacy and safety of phototherapy in treating pityriasis lichenoides chronica in paediatric patients. IJSR 2021:50-1.
Filippi F, Baraldi C, Zinzani PL, Casadei B, Pileri A. A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford–AstraZeneca COVID‐19 vaccine. J Eur Acad Dermatol Venereol. 2022 Jun 7:10-111.
Tahir M, Elkadi O, Liu SS, Dasaraju S. Pityriasis Lichenoides Chronica of Esophagus: A Rare Case Report. Cureus. 2022 Dec 7;14(12):e32290.
Cortez-Vila JA, Lacy-Niebla RM. Dual cutaneous lymphoid dyscrasias in a pediatric patient, with progression to mycosis fungoides: case report. Int J Contemp Pediatr. 2024 Apr;11(4):475.
Salah EM, Bedair NI, El‐Rahim SK, El‐Khalawany MA. Efficacy and safety of excimer light (308 nm) in the treatment of pityriasis lichenoides chronica. Photodermatol Photoimmunol Photomed. 2024 May;40(3):e12964.
Adistri, Kara & Budianti, Windy & Amalia, Sarly. Pityriasis lichenoides chronica successfully treated with combination of narrowband UVB phototherapy and cyclosporine: a case report. Iranian J Dermatol. 2023;26:90-94. 10.22034/ijd.2022.305725.1435.
Chen Y, Zhao M, Xiang X, Wang Z, Xu Z, Ma L. Oral erythromycin in pityriasis lichenoides chronica and pityriasis lichenoides et varioliformis acuta. Dermatol Ther. 2020 May;33(3):e13311.
Lowe E, Jacobsen JR, Taylor S, Miller R, Price HN, Andrews ID. Mycosis fungoides preceding pityriasis lichenoides et varioliformis acuta by twelve years in a pediatric patient. Am J Dermatopathol. 2021 Dec 1;43(12):e259-62.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Pakistan Association of Dermatologists
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
